- Pharmazeutisches Institut
- medicinal chemistry
- epigenetics
- PROTACs
Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kroeger T, Ernst T, Koegler G, Krieg A, Luedeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz F, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J (2018) Targeting HSP90 dimerization via the C-terminus is effective in imatinib resistant CML and lacks the heat shock response. Blood 132:307–320.
Bhatia S, Krieger V, Groll M, Osko JD, Reßing N., Ahlert H, Borkhardt A, Kurz T, Christianson DW, Hauer J, Hansen FK (2018) Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor. J Med Chem 61:10299–10309.
Sinatra L, Bandolik JJ, Roatsch M, Sönnichsen M, Schoeder CT, Hamacher A, Schöler A, Borkhardt A, Meiler J, Bhatia S, Kassack MU, Hansen, FK (2020) Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual Targeting HDAC Inhibitors and HDAC Degraders (PROTACs). Angew Chem Int Ed 59:22494–22499.
Selg C, Schöler A, Schliehe-Diecks J, Hanl M, Sinatra L, Borkhardt A, Sárosi MB, Bhatia S, Hey-Hawkins E, Hansen FK (2021) Borinostats: Solid-Phase Synthesis of Carborane-Capped Histone Deacetylase Inhibitors with a Tailor-Made Selectivity Profile. Chem Sci 12:11873–11881.